

AMENDMENTS TO THE CLAIMS:

This listing of claims will replace all prior versions, and listings, of claims in the application:

LISTING OF CLAIMS:

1-35. (canceled)

36. (currently amended) A process for preparing a monoclonal antibody directed against endothelial cells with an angiogenic phenotype that is capable of inhibiting angiogenesis, said antibody ~~having the following characteristics~~ being characterized by:

said antibody binds to a surface of the endothelial cells with an angiogenic phenotype, and

said antibody recognizes a unit present exclusively on the endothelial cells with an angiogenic phenotype,

said endothelial cells having an angiogenic phenotype being obtained by culturing endothelial cells removed from an aorta in a medium containing a supplement consisting essentially of oestradiol and VEGF,

said endothelial cells with an angiogenic phenotype ~~having the following properties~~ being such that:

said endothelial cells form tubes in presence of growth factor VEGF in a collagen gel,

said endothelial cells proliferate under action of VEGF,

said endothelial cells are protected from apoptosis by VEGF, and

said endothelial ~~cells~~ cells' expression of VEGFR-2 is increased 4-fold in comparison with cells with a non-angiogenic phenotype,

comprising the steps of:

immunizing an animal by injection of said endothelial cells with an angiogenic phenotype;

fusing myelomas of an animal and splenocytes of [[an]] said animal in order to obtain hybridomas;

preparing a culture of said hybridomas;

cloning of said hybridomas and secreting antibodies against endothelial cells with an angiogenic phenotype; and

verifying that said antibodies inhibit said properties of said cells with an angiogenic phenotype.

37-48. (canceled)